

# ThromboGenics Full Year Results 2015 Conference Call Presentation



# Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation slides,

you agree to be bound by the following limitations:

This document has been prepared by ThromboGenics NV (the "Company") and is being supplied to you solely for your information and use by you at the Company presentation. This document and its contents are confidential and may not be further distributed or passed on to any other person or published or reproduced, in whole or in part, by any medium or in any form for any purpose. All the numerical data provided in this document are derived from ThromboGenics' consolidated financial statements.

No representation or warranty expressed or implied is or will be made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained herein. The information set out herein may be subject to updating, completion, revision, verification, and amendment, and such information may change materially. The Company is under no obligation to update or keep current the information contained in this document or the presentation to which it relates, and any opinions expressed in it are subject to change without notice. None of the Company or any of its affiliates, its advisors, or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this document or its contents or otherwise arising in connection with this document.

The following information does not constitute investment advice, and shall not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

# Highlights 2015

- A drug development company developing innovative treatments for the back of the eye disease, with a focus on diabetic eye disease
- Significant research and development progress – generated pipeline of disease modifying treatments for diabetic retinopathy (DR), with or without diabetic macular edema (DME)
- US commercial organization supporting JETREA® right sized to ensure US operations are break-even starting in 2016
- 2015 reported sales are €11.2 million
- Cash resources of around €100 million to support clinical development plans for the next 3 years
  - position to deliver a number of potential value-generating milestones

# Financial Review 2015

€ Million	FY 2015	FY 2014
Revenue	11.2*	13.8**
<i>US</i>	<i>7.4</i>	<i>8.8</i>
<i>Ex-US</i>	<i>3.2</i>	<i>3.4</i>
R&D expenses	21.4	22.6
Selling expenses	17.6	29.9
Net loss	(37.9)	(51.1)
EPS (€)	(1.05)	(1.42)


\* Including €0.5 million from LSRP

\*\* Including €1.4 million of products recharged to Alcon + € 0.2 million other income

# Cash management

- Cash and investments of €101.4 million end December 2015 (€127.1 million end December 2014)
- Tight cash management
- US operation expected to be break-even in 2016
- Available cash plus JETREA<sup>®</sup> royalty income should fund current development activities for next 3 years

# Diabetic retinopathy segment growing twice as fast as overall ophthalmic pharmaceuticals market



\* Incl. 'anti-glaucoma', 'anti-allergy/inflammatory/infective', 'retinal disorders', 'dry eye', and 'others' markets

\*\* Incl. at least wet AMD, DR/DME, and RVO markets

Abbreviation(s): AMD, age-related macular degeneration; DR, diabetic retinopathy; DME, diabetic macular edema; RVO, retinal vein occlusion; CAGR, compound annual growth rate

Source(s): adapted from Visiongain 2008, Visiongain 2012, Datamonitor Healthcare 2015, and Technavio Insights 2015

# More than **one** in **three** living with diabetes will develop some form of diabetic retinopathy in their lifetime

35.4%



ANY DR\*

Diabetes is increasing and so is diabetic eye disease


DR affects over one third of all people with diabetes and is the leading cause of vision loss in working-age adults

DME is a consequence of DR, and can happen at any stage of disease

\* Any DR is defined as the presence of NPDR, PDR, DME or any combination thereof

Abbreviation(s): DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; DME, diabetic macular edema; VTDR, vision-threatening diabetic retinopathy  
Source(s): Yau 2012; Int'l Diabetes Federation and the Fred Hollows Foundation 2015; National Eye Institute 2015

# ThromboGenics is developing therapies for all DR segments



\* Any DR is defined as the presence of NPDR, PDR, DME or any combination thereof  
Abbreviation(s): DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; DME, diabetic macular edema;  
Source(s): Yau 2012; Int'l Diabetes Federation and the Fred Hollows Foundation 2015; National Eye Institute 2015



# New pipeline - novel disease modifying DR treatments

- **THR-409** – on-going Phase IIa (CIRCLE) clinical study evaluating the efficacy and safety of multiple doses of ocriplasmin to induce a total posterior vitreous detachment (PVD) in patients with NPDR to prevent progression to PDR
- **THR-317** – a PLGF neutralizing monoclonal antibody being developed for DME and/or for use in combination with current anti-VEGF treatments
- **THR-149** – a plasma kallikrein inhibitor to treat DME associated with diabetic retinopathy.
- **THR-687** – a small molecule integrin antagonist being developed to treat a broad range of patients with diabetic retinopathy, with or without DME.

# Oncurious - TB-403 Phase I/IIa trial to start in Q2 2016

- Focused on development of innovative orphan drugs for treatment of pediatric cancers
- Phase I/IIa : developing TB-403 for the treatment of medulloblastoma, a rare, life-threatening pediatric cancer
  - TB-403 is a humanized monoclonal antibody against placental growth factor (PIGF). PIGF is expressed in several types of cancer, including medulloblastoma.
  - PIGF plays a vital role in the brain and its expression is required for the growth and spread of medulloblastoma (Cell, 152, 1065-76, 2013)
- Clinical trial collaboration signed with the Neuroblastoma and Medulloblastoma Translational Research Center (NMTRC), a non-profit US organisation and clinical trial network with the mission to bring forward new effective therapies against neuroblastoma and medulloblastoma
- Phase I/IIa program : enrollment of first patient in the US expected by Q2 2016

# ThromboGenics today : disease modifying treatments for diabetic eye disease

## Diabetic Eye Disease

Disease Modifying Treatments Tackling Unmet  
Medical Needs in  
Diabetic Retinopathy

THR-409 – ocriplasmin  
THR-317 – anti-PIGF  
THR-149 – plasma kallikrein inhibitor  
THR-687 – integrin antagonist

For NPDR/PDR  
with or without DME

€ 100 million in cash  
+ royalties and other  
revenues

## ONCURIOUS

TB-403 for  
medulloblastoma

Phase I/IIa  
Q2 2016

+ Third party investment  
Self-sustaining

## JETREA US

Break-even  
From 2016

Self-sustaining

Learn more about our Diabetic Eye Disease pipeline?

INVITATION – London March 18, 3 – 5PM CET



Novel Disease Modifying Approaches for Diabetic Eye Disease  
A Portfolio Update

Research & Development – Investor Meeting  
London, March 18 2016

For meeting registration and webcast details,  
please consult [www.thrombogenics.com](http://www.thrombogenics.com)

# Questions & Answers

